Market Research Logo

Immuno-Oncology Drugs Market Size and Share, By Drug and Cancer Type - Global Industry Insights, Trends, Outlook, and Opportunity Analysis 2017-2025

Immuno-Oncology Drugs Market Size and Share, By Drug and Cancer Type - Global Industry Insights, Trends, Outlook, and Opportunity Analysis 2017-2025

Natural immunity system holds superior potential to specifically target and destruct tumors while avoiding harm to the normal healthy tissue along with long term memory to prevent cancer recurrence. Immuno-oncology research has supported the fact that immunity system can effectively identify tumors and can stop or control long term growth of the same through immunosurveillance. However, cancer progression leads to suppression of immunity systems natural functioning wherein immune-oncology therapies play an important role. Advent of innovative immune-oncology therapies such as immune-checkpoint inhibitors, therapeutic cancer vaccines, and CAR-T therapies has spurred leading organizations to actively invest into research and development. However, high costs associated with therapy is restraining growth of the immuno-oncology drugs market.
Market Dynamics
Global Immuno-oncology drugs market is driven by factors such as increasing prevalence of cancer, active research and development by leading manufacturers through collaborations and individual research, and robust pipeline. According to World Health Organization (WHO), cancer is one of the major non-communicable diseases and the second-leading cause of death worldwide. According to International Agency for Research on Cancer (IARC) in 2012, there were around 14.1 million new cases, around 8.8 million deaths, and around 32.6 million of people suffering from cancer worldwide. There are many immuno-oncology drugs in the pipeline such as CAR-T cell therapy offered by Juno Therapeutics, Inc. and Kite Pharma. Immuno-oncology drugs has proven clinical profile and increasing approvals to include more indication for existing drugs such as Nivolumab, which in turn is expected to boost growth of the immuno-oncology drugs market.
Key features of the study:

This report provides in-depth analysis of global immuno-oncology drugs market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017–2025), considering 2016 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global immuno-oncology drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies
Key companies covered as a part of this study include Amgen, Inc. AstraZeneca Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie, Inc., Pfizer Inc., Sanofi S.A., EMD Serono, Inc., Gilead Sciences Inc., Prometheus Therapeutics & Diagnostics, Aduro BioTech, Galena Biopharma, Bavarian Nordic, Celldex Therapeutics, ImmunoCellular Therapeutics, and Incyte
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, By Technology up-gradation, market expansion, and marketing tactics
The global immuno-oncology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the global immuno-oncology drugs market

Detailed Segmentation:

Global Immuno-Oncology Drugs Market, By Drug Type:

Immune Checkpoint Inhibitors

CTL-4 Checkpoint Inhibitor

Iplimumab

PD-1 & PD-L1 Checkpoint Inhibitor

Nivolumab (Opdivo)
Atezolimumab (Tecentriq)
Pembrolizumab (Keytruda)
Avelumab (Bavencio)
Durvalumab (Imfinzi)

Monoclonal Antibodies

Naked Monoclonal Antibodies

Rituximab (Rituxan)
Trastazumab (Herceptin)
Bevacizumab (Avastin)
Others

Conjugated Monoclonal Antibodies

Radiolabeled Antibodies

Ibrotumomab Tiuxetan (Zevalin)

Chemo labeled Antibodies

Brentixumab Vedotin (Adcetris)
Trastuzumab Emtansine (Kadcyla)

Bispecific Monoclonal Antibodies

Blinatumomab (Blincyto)

Cytokine Based Immunotherapy

Intron A
Proleukin

Cancer Vaccines

Preventive Vaccines

Gardasil
Cervarix

Treatment Vaccines

Sipuleucel-T (Provenge)

CAR-T Cell Therapy

Kymriah
Yescarta

Global Immuno-Oncology Drugs Market, By Cancer Type:

Non-Small Cell Lung Cancer
Acute Myeloid Leukemia
Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma)
Multiple Myeloma
Breast Cancer
Ovarian Cancer
Prostate Cancer
Colorectal Cancer
Gastric Cancers
Glioblastoma
Head & Neck Cancers

Global Immuno-Oncology Drugs Market, By Geography:

North America

By Drug Type

Immune Checkpoint Inhibitors

CTL-4 Checkpoint Inhibitor

Iplimumab

PD-1 & PD-L1 Checkpoint Inhibitor

Nivolumab (Opdivo)
Atezolimumab (Tecentriq)
Pembrolizumab (Keytruda)
Avelumab (Bavencio)
Durvalumab (Imfinzi)

Monoclonal Antibodies

Naked Monoclonal Antibodies

Rituximab (Rituxan)
Trastazumab (Herceptin)
Bevacizumab (Avastin)
Others

Conjugated Monoclonal Antibodies

Radiolabeled Antibodies

Ibrotumomab Tiuxetan (Zevalin)

Chemo labeled Antibodies

Brentixumab Vedotin (Adcetris)
Trastuzumab Emtansine (Kadcyla)

Bispecific Monoclonal Antibodies

Blinatumomab (Blincyto)

Cytokine Based Immunotherapy

Intron A
Proleukin

Cancer Vaccines

Preventive Vaccines

Gardasil
Cervarix

Treatment Vaccines

Sipuleucel-T (Provenge)

CAR-T Cell Therapy

Kymriah
Yescarta      

By Cancer Type:

Non-Small Cell Lung Cancer
Acute Myeloid Leukemia
Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma)
Multiple Myeloma
Breast Cancer
Ovarian Cancer
Prostate Cancer
Colorectal Cancer
Gastric Cancers
Glioblastoma
Head & Neck Cancers

By Country:

U.S.
Canada

Europe

By Drug Type

Immune Checkpoint Inhibitors

CTL-4 Checkpoint Inhibitor

Iplimumab

PD-1 & PD-L1 Checkpoint Inhibitor

Nivolumab (Opdivo)
Atezolimumab (Tecentriq)
Pembrolizumab (Keytruda)
Avelumab (Bavencio)
Durvalumab (Imfinzi)

Monoclonal Antibodies

Naked Monoclonal Antibodies

Rituximab (Rituxan)
Trastazumab (Herceptin)
Bevacizumab (Avastin)
Others

Conjugated Monoclonal Antibodies

Radiolabeled Antibodies

Ibrotumomab Tiuxetan (Zevalin)

Chemo labeled Antibodies

Brentixumab Vedotin (Adcetris)
Trastuzumab Emtansine (Kadcyla)

Bispecific Monoclonal Antibodies

Blinatumomab (Blincyto)

Cytokine Based Immunotherapy

Intron A
Proleukin

Cancer Vaccines

Preventive Vaccines

Gardasil
Cervarix

Treatment Vaccines

Sipuleucel-T (Provenge)

CAR-T Cell Therapy

Kymriah
Yescarta

By Cancer Type:

Non-Small Cell Lung Cancer
Acute Myeloid Leukemia
Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma)
Multiple Myeloma
Breast Cancer
Ovarian Cancer
Prostate Cancer
Colorectal Cancer
Gastric Cancers
Glioblastoma
Head & Neck Cancers

By Country:

U.K.
Germany
Italy
France
Russia
Spain
Rest of Europe

Asia Pacific

By Drug Type

Immune Checkpoint Inhibitors

CTL-4 Checkpoint Inhibitor

Iplimumab

PD-1 & PD-L1 Checkpoint Inhibitor

Nivolumab (Opdivo)
Atezolimumab (Tecentriq)
Pembrolizumab (Keytruda)
Avelumab (Bavencio)
Durvalumab (Imfinzi)

Monoclonal Antibodies

Naked Monoclonal Antibodies

Rituximab (Rituxan)
Trastazumab (Herceptin)
Bevacizumab (Avastin)
Others

Conjugated Monoclonal Antibodies

Radiolabeled Antibodies

Ibrotumomab Tiuxetan (Zevalin)

Chemo labeled Antibodies

Brentixumab Vedotin (Adcetris)
Trastuzumab Emtansine (Kadcyla)

Bispecific Monoclonal Antibodies

Blinatumomab (Blincyto)

Cytokine Based Immunotherapy

Intron A
Proleukin

Cancer Vaccines

Preventive Vaccines

Gardasil
Cervarix

Treatment Vaccines

Sipuleucel-T (Provenge)

CAR-T Cell Therapy

Kymriah
Yescarta

By Cancer Type:

Non-Small Cell Lung Cancer
Acute Myeloid Leukemia
Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma)
Multiple Myeloma
Breast Cancer
Ovarian Cancer
Prostate Cancer
Colorectal Cancer
Gastric Cancers
Glioblastoma
Head & Neck Cancers

By Country:

China
India
Japan
ASEAN
Australia
South Korea
Rest of APAC

Latin America

By Drug Type

Immune Checkpoint Inhibitors

CTL-4 Checkpoint Inhibitor

Iplimumab

PD-1 & PD-L1 Checkpoint Inhibitor

Nivolumab (Opdivo)
Atezolimumab (Tecentriq)
Pembrolizumab (Keytruda)
Avelumab (Bavencio)
Durvalumab (Imfinzi)

Monoclonal Antibodies

Naked Monoclonal Antibodies

Rituximab (Rituxan)
Trastazumab (Herceptin)
Bevacizumab (Avastin)
Others

Conjugated Monoclonal Antibodies

Radiolabeled Antibodies

Ibrotumomab Tiuxetan (Zevalin)

Chemo labeled Antibodies

Brentixumab Vedotin (Adcetris)
Trastuzumab Emtansine (Kadcyla)

Bispecific Monoclonal Antibodies

Blinatumomab (Blincyto)

Cytokine Based Immunotherapy

Intron A
Proleukin

Cancer Vaccines

Preventive Vaccines

Gardasil
Cervarix

Treatment Vaccines

Sipuleucel-T (Provenge)

CAR-T Cell Therapy

Kymriah
Yescarta

By Cancer Type:

Non-Small Cell Lung Cancer
Acute Myeloid Leukemia
Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma)
Multiple Myeloma
Breast Cancer
Ovarian Cancer
Prostate Cancer
Colorectal Cancer
Gastric Cancers
Glioblastoma
Head & Neck Cancers

By Country:

Brazil
Mexico
Argentina
Rest of LATAM

Middle East

By Drug Type

Immune Checkpoint Inhibitors

CTL-4 Checkpoint Inhibitor

Iplimumab

PD-1 & PD-L1 Checkpoint Inhibitor

Nivolumab (Opdivo)
Atezolimumab (Tecentriq)
Pembrolizumab (Keytruda)
Avelumab (Bavencio)
Durvalumab (Imfinzi)

Monoclonal Antibodies

Naked Monoclonal Antibodies

Rituximab (Rituxan)
Trastazumab (Herceptin)
Bevacizumab (Avastin)
Others

Conjugated Monoclonal Antibodies

Radiolabeled Antibodies

Ibrotumomab Tiuxetan (Zevalin)

Chemo labeled Antibodies

Brentixumab Vedotin (Adcetris)
Trastuzumab Emtansine (Kadcyla)

Bispecific Monoclonal Antibodies

Blinatumomab (Blincyto)

Cytokine Based Immunotherapy

Intron A
Proleukin

Cancer Vaccines

Preventive Vaccines

Gardasil
Cervarix

Treatment Vaccines

Sipuleucel-T (Provenge)

CAR-T Cell Therapy

Kymriah
Yescarta

By Cancer Type:

Non-Small Cell Lung Cancer
Acute Myeloid Leukemia
Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma)
Multiple Myeloma
Breast Cancer
Ovarian Cancer
Prostate Cancer
Colorectal Cancer
Gastric Cancers
Glioblastoma
Head & Neck Cancers

By Country:

GCC
Israel
Rest of Middle East

Africa

By Drug Type

Immune Checkpoint Inhibitors

CTL-4 Checkpoint Inhibitor

Iplimumab

PD-1 & PD-L1 Checkpoint Inhibitor

Nivolumab (Opdivo)
Atezolimumab (Tecentriq)
Pembrolizumab (Keytruda)
Avelumab (Bavencio)
Durvalumab (Imfinzi)

Monoclonal Antibodies

Naked Monoclonal Antibodies

Rituximab (Rituxan)
Trastazumab (Herceptin)
Bevacizumab (Avastin)
Others

Conjugated Monoclonal Antibodies

Radiolabeled Antibodies

Ibrotumomab Tiuxetan (Zevalin)

Chemo labeled Antibodies

Brentixumab Vedotin (Adcetris)
Trastuzumab Emtansine (Kadcyla)

Bispecific Monoclonal Antibodies

Blinatumomab (Blincyto)

Cytokine Based Immunotherapy

Intron A
Proleukin

Cancer Vaccines

Preventive Vaccines

Gardasil
Cervarix

Treatment Vaccines

Sipuleucel-T (Provenge)

CAR-T Cell Therapy

Kymriah
Yescarta

By Cancer Type:

Non-Small Cell Lung Cancer
Acute Myeloid Leukemia
Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma)
Multiple Myeloma
Breast Cancer
Ovarian Cancer
Prostate Cancer
Colorectal Cancer
Gastric Cancers
Glioblastoma
Head & Neck Cancers

By Country:

North Africa
Central Africa
South Africa

Company Profiles

Amgen, Inc.*

Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments

AstraZeneca, Plc
Bristol-Myers Squibb
Celgene Corporation
Eli Lilly and Company
Merck & Co.
Hoffmann-La Roche AG
Johnson & Johnson
Novartis International AG
AbbVie, Inc.
Pfizer Inc.
Sanofi S.A.
EMD Serono, Inc.
Gilead Sciences Inc.
Prometheus Therapeutics & Diagnostics
Aduro BioTech
Galena Biopharma
Bavarian Nordic
Celldex Therapeutics
ImmunoCellular Therapeutics
Incyte

 “*” marked represents similar segmentation in other categories in the respective section.


1. Research Objective and assumption
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Drug Type
Market Snippet, By Cancer Type
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Immuno-Oncology Overview
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Key Highlights
PEST Analysis
PORTER’s Five Forces Analysis
Mergers & Acquisitions
Epidemiology
Research Update & Pipeline Analysis (For each drug category)
Major FDA Approvals & Product Launch Scenario (For each drug category)
Regulatory Scenario
Reimbursement Scenario
Immunotherapy Combination Therapies In Development
Adoptive Cell Transfer Therapies
4. Global Immuno-Oncology Drugs Market, By Drug Type, 2017–2025 (US$ Mn)
Introduction
Market Share Analysis, 2016 and 2025 (%)
Y-o-Y Growth Analysis, 2016–2025
Segment Trends
Immune Checkpoint Inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
CTL-4 Checkpoint Inhibitor
Iplimumab
PD-1 & PD-L1 Checkpoint Inhibitor
Nivolumab (Opdivo)
Atezolimumab (Tecentriq)
Pembrolizumab (Keytruda)
Avelumab (Bavencio)
Durvalumab (Imfinzi)
Monoclonal Antibodies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
Naked Monoclonal Antibodies
Rituximab (Rituxan)
Trastazumab (Herceptin)
Bevacizumab (Avastin)
Others
Conjugated Monoclonal Antibodies
Radiolabeled Antibodies
1. Ibrotumomab Tiuxetan (Zevalin)
Chemo labeled Antibodies
1. Brentixumab Vedotin (Adcetris)
2. Trastuzumab Emtansine (Kadcyla)
Bispecific Monoclonal Antibodies
1. Blinatumomab (Blincyto)
Cytokine Based Immunotherapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
Intron A
Proleukin
Cancer Vaccines
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
Preventive Vaccines
Gardasil
Cervarix
Treatment Vaccines
Sipuleucel-T (Provenge)
CAR-T Cell Therapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
Kymriah
Yescarta
5. Global Immuno-Oncology Drugs Market, By Cancer Type, 2017–2025 (US$ Mn)
Introduction
Market Share Analysis, 2016 and 2025 (%)
Y-o-Y Growth Analysis, 2016–2025
Segment Trends
Non-Small Cell Lung Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
Acute Myeloid Leukemia
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
Multiple Myeloma
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
Breast Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
Ovarian Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
Prostate Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
Colorectal Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
Gastric Cancers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
Glioblastoma
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
Head & Neck Cancers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
6. Global Immuno-Oncology Drugs Market, By Regions, 2017–2025 (US$ Mn)
Introduction
Market Share Analysis, By Region, 2016 and 2025 (%)
Y-o-Y Growth Analysis, For Regions, 2016–2025
North America
Market Size and Forecast, By Drug Type, 2015–2025 (US$ Mn)
Market Size and Forecast, By Cancer Type, 2015–2025 (US$ Mn)
Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
U.S.
Canada
Europe
Market Size and Forecast, By Drug Type, 2015–2025 (US$ Mn)
Market Size and Forecast, By Cancer Type, 2015–2025 (US$ Mn)
Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Market Size and Forecast, By Drug Type, 2015–2025 (US$ Mn)
Market Size and Forecast, By Cancer Type, 2015–2025 (US$ Mn)
Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of APAC
Latin America
Market Size and Forecast, By Drug Type, 2015–2025 (US$ Mn)
Market Size and Forecast, By Cancer Type, 2015–2025 (US$ Mn)
Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
Brazil
Mexico
Argentina
Rest of LATAM
Middle East
Market Size and Forecast, By Drug Type, 2015–2025 (US$ Mn)
Market Size and Forecast, By Cancer Type, 2015–2025 (US$ Mn)
Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
Market Size and Forecast, By Drug Type, 2015–2025 (US$ Mn)
Market Size and Forecast, By Cancer Type, 2015–2025 (US$ Mn)
Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
North Africa
Central Africa
South Africa
7. Competitive Landscape
Heat Map Analysis
Company Profiles
Amgen, Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
AstraZeneca Plc
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Bristol-Myers Squibb
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Celgene Corporation
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Eli Lilly and Company
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Merck & Co.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
F. Hoffmann-La Roche AG
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Johnson & Johnson
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Novartis International AG
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
AbbVie, Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Pfizer Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Sanofi S.A.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
EMD Serono, Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Gilead Sciences Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Prometheus Therapeutics & Diagnostics
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Aduro BioTech
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Galena Biopharma
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Bavarian Nordic
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Celldex Therapeutics
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
ImmunoCellular Therapeutics
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Incyte
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
8. Section
References
Research Methodology
About us and Sales Contact
*Browse 25 market data tables and 38 figures on "Immuno-Oncology Drugs Market - Global forecast to 2025”

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report